These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 23283289

  • 41. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.
    Uehara R, Belay ED, Maddox RA, Holman RC, Nakamura Y, Yashiro M, Oki I, Ogino H, Schonberger LB, Yanagawa H.
    Pediatr Infect Dis J; 2008 Feb; 27(2):155-60. PubMed ID: 18174868
    [Abstract] [Full Text] [Related]

  • 42. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease.
    Newburger JW, Sleeper LA, McCrindle BW, Minich LL, Gersony W, Vetter VL, Atz AM, Li JS, Takahashi M, Baker AL, Colan SD, Mitchell PD, Klein GL, Sundel RP, Pediatric Heart Network Investigators.
    N Engl J Med; 2007 Feb 15; 356(7):663-75. PubMed ID: 17301297
    [Abstract] [Full Text] [Related]

  • 43. [Kawasaki disease].
    Cimaz R, Lega JC.
    Rev Prat; 2007 Nov 30; 57(18):1985-8. PubMed ID: 18326430
    [Abstract] [Full Text] [Related]

  • 44. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial.
    Sundel RP, Baker AL, Fulton DR, Newburger JW.
    J Pediatr; 2003 Jun 30; 142(6):611-6. PubMed ID: 12838187
    [Abstract] [Full Text] [Related]

  • 45. Revisiting steroids in the primary treatment of acute Kawasaki disease.
    Burns JC.
    J Pediatr; 2006 Sep 30; 149(3):291-2. PubMed ID: 16939734
    [No Abstract] [Full Text] [Related]

  • 46. Infliximab as a novel therapy for refractory Kawasaki disease.
    Weiss JE, Eberhard BA, Chowdhury D, Gottlieb BS.
    J Rheumatol; 2004 Apr 30; 31(4):808-10. PubMed ID: 15088313
    [Abstract] [Full Text] [Related]

  • 47. Re-treatment regimens for acute stage of Kawasaki disease patients who failed to respond to initial intravenous immunoglobulin therapy: analysis from the 17th nationwide survey.
    Uehara R, Yashiro M, Oki I, Nakamura Y, Yanagawa H.
    Pediatr Int; 2007 Aug 30; 49(4):427-30. PubMed ID: 17587262
    [Abstract] [Full Text] [Related]

  • 48. Guideline-Concordant Treatment of Kawasaki Disease With Immunoglobulin and Aspirin and the Incidence of Coronary Artery Aneurysm.
    Michihata N, Matsui H, Fushimi K, Yasunaga H.
    Clin Pediatr (Phila); 2015 Oct 30; 54(11):1076-80. PubMed ID: 25573948
    [Abstract] [Full Text] [Related]

  • 49. Update on the treatment of Kawasaki disease in childhood.
    Sundel RP.
    Curr Rheumatol Rep; 2002 Dec 30; 4(6):474-82. PubMed ID: 12427361
    [Abstract] [Full Text] [Related]

  • 50. [Clinical features and course of Kawasaki disease in central Tunisia: a study about 14 cases collected over a period of three years (2000-2002)].
    Chemli J, Kchaou H, Amri F, Belkadhi A, Essoussi AS, Gueddiche N, Harbi A.
    Tunis Med; 2005 Aug 30; 83(8):477-83. PubMed ID: 16238276
    [Abstract] [Full Text] [Related]

  • 51. A 5-year-old boy with fever and rash. Incomplete Kawasaki disease.
    Kallada S.
    Pediatr Ann; 2011 Apr 30; 40(4):185-7. PubMed ID: 21485993
    [No Abstract] [Full Text] [Related]

  • 52. Infliximab as the First Retreatment in Patients with Kawasaki Disease Resistant to Initial Intravenous Immunoglobulin.
    Youn Y, Kim J, Hong YM, Sohn S.
    Pediatr Infect Dis J; 2016 Apr 30; 35(4):457-9. PubMed ID: 26673981
    [Abstract] [Full Text] [Related]

  • 53. Recent advances in the treatment of Kawasaki disease.
    Weng KP, Ou SF, Lin CC, Hsieh KS.
    J Chin Med Assoc; 2011 Nov 30; 74(11):481-4. PubMed ID: 22100015
    [Abstract] [Full Text] [Related]

  • 54. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease.
    Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS, Melish ME, Jackson MA, Asmar BI, Lang DJ, Connor JD, Capparelli EV, Keen ML, Mamun K, Keenan GF, Ramilo O.
    J Pediatr; 2008 Dec 30; 153(6):833-8. PubMed ID: 18672254
    [Abstract] [Full Text] [Related]

  • 55. A national survey on the pediatric cardiologist's clinical approach for patients with Kawasaki disease.
    Kahwaji IY, Connuck DM, Tafari N, Dahdah NS.
    Pediatr Cardiol; 2002 Dec 30; 23(6):639-46. PubMed ID: 12530498
    [Abstract] [Full Text] [Related]

  • 56. Kawasaki disease.
    Burns JC.
    Adv Pediatr; 2001 Dec 30; 48():157-77. PubMed ID: 11480756
    [Abstract] [Full Text] [Related]

  • 57. Infections and Kawasaki disease: implications for coronary artery outcome.
    Benseler SM, McCrindle BW, Silverman ED, Tyrrell PN, Wong J, Yeung RS.
    Pediatrics; 2005 Dec 30; 116(6):e760-6. PubMed ID: 16322132
    [Abstract] [Full Text] [Related]

  • 58. Kawasaki disease.
    Kim DS.
    Yonsei Med J; 2006 Dec 31; 47(6):759-72. PubMed ID: 17191303
    [Abstract] [Full Text] [Related]

  • 59. Management and outcome of intravenous gammaglobulin-resistant Kawasaki disease.
    Sittiwangkul R, Pongprot Y, Silvilairat S, Phornphutkul C.
    Singapore Med J; 2006 Sep 31; 47(9):780-4. PubMed ID: 16924360
    [Abstract] [Full Text] [Related]

  • 60. Infliximab reduces the cytokine-mediated inflammation but does not suppress cellular infiltration of the vessel wall in refractory Kawasaki disease.
    Hirono K, Kemmotsu Y, Wittkowski H, Foell D, Saito K, Ibuki K, Watanabe K, Watanabe S, Uese K, Kanegane H, Origasa H, Ichida F, Roth J, Miyawaki T, Saji T.
    Pediatr Res; 2009 Jun 31; 65(6):696-701. PubMed ID: 19430379
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.